By: IPP Bureau
Last updated : May 04, 2022 3:45 pm
Bortezomib for injection is used to treat certain types of cancer such as multiple myeloma and mantle cell lymphoma
Gland Pharma through its partner has launched Bortezomib for Injection, 3.5 mg/vial, single-dose vial in the US Market. It is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Velcade for Injection, 3.5 mg/vial of Takeda Pharmaceuticals U.S.A.
Bortezomib for injection is used to treat certain types of cancer such as multiple myeloma and mantle cell lymphoma.
Velcade has a market size of US $ 1,172 million for the twelve months ending March 2022, according to IQVIA.
Gland Pharma's partner has received the ANDA approval for the product from U.S. Food & Drug Administration (US FDA). Gland Pharma is manufacturing and supplying this product to its partner for the US market.